



Sosei Subsidiary Heptares and Teva Enter Agreement to Discover and Develop Novel Small Molecule CGRP Antagonists for Treatment of Migraine

- *Teva to receive worldwide development and commercial rights to novel CGRP antagonists*
- *Heptares to receive \$10 million upfront with up to \$400 million in potential milestone payments*

Tokyo, Japan – 25 November 2015: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces that its wholly-owned subsidiary Heptares Therapeutics (“Heptares”) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA, “Teva”), have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.

Under the terms of the agreement, Heptares will receive an upfront payment of \$10 million, research funding, and is eligible to receive additional research, development and commercialization milestone payments of up to \$400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.

“We are delighted to begin this partnership with Heptares, which through its industry-leading, structure-based design approach has generated novel CGRP antagonists with significant promise for treating migraine,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody.”

“This agreement is an exciting development for our CGRP antagonist program,” added Malcolm Weir, Chief Executive Officer of Heptares and Chief R&D Officer of Sosei Group. “Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”

-Ends-

Enquiries:

Sosei Group Corporation
Tokyo Office
Milica STOJKOVIC,
Corporate Communications
+81-(0)3-5210-3399
mstojkovic@sosei.com

London Office
Kathryn LYDON,
Corporate Communications
+44-(0)20-7691-0983
klydon@sosei.com

Notes to Editors

About Migraine

Approximately 36 million people in the United States¹ and 8 million patients in Japan² suffer from migraine. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide.³ Migraine is defined as recurring attacks of moderate to severe headache pain. The International Headache Society defines chronic migraine as more than fifteen headache days per month over a three month period of which more than eight are migraines, in the absence of medication over use. Episodic migraine is the other migraine sub-type, which is defined as less than 15 headache days per month.⁴ During migraines, people can experience varying characteristics such as being very sensitive to light and sound and may also experience nausea and vomiting.⁵ There is no absolute cure for migraine since its pathophysiology has yet to be fully understood.³

About CGRP Antagonists for Migraine

Calcitonin gene-related peptide (CGRP) is released during migraine attacks and can trigger migraine in patients.⁶ CGRP is found in small to medium-sized neurons in the trigeminal ganglion and mediates its activity through G protein-coupled receptors located throughout the body. Elevated levels of CGRP are found in migraineurs during an attack and blocking CGRP activity is a validated mechanism of action for relieving pain, and also for preventing migraine.⁷

About Sosei

Sosei is a biopharmaceutical company originating from Japan but with global presence. Sosei's primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide. For further information about Sosei, please visit www.sosei.com/en.

About Heptares Therapeutics

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Using this approach, we have built an exciting pipeline of new medicines with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immuno-oncology, migraine, addiction, metabolic disease, and other indications. Pharmaceutical partners include AstraZeneca, MedImmune, MorphoSys, Takeda and Teva. Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit www.heptares.com and www.sosei.com.

*HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;
StaR[®] is a registered trademark in the EU and Japan.*

About Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to

produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to \$20.3 billion. For more information, visit www.tevapharm.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

-
1. Lipton RB, Bigal ME, Diamond M, *et al.*; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventative therapy. *Neurology* 2007; 68(5):343-349.
 2. Sakai F, Igarashi H; Prevalence of migraine in Japan: a nationwide survey. *Cephalalgia* 1997; 17:15-22
 3. National Institute of Neurological Disorders and Stroke. (2014). Migraine. Available at: <http://www.ninds.nih.gov/disorders/migraine/migraine.htm>.
 4. Olesen J, Bousser MG, Diener HC *et al.*; New appendix criteria open for a broader concept of chronic migraine. *Cephalalgia* 2006; 26:742-746
 5. National Institutes of Health. (2015). Migraine. Available at: <http://www.nlm.nih.gov/medlineplus/migraine.html>.
 6. Ho TW, Edvinsson L, Goadsby PJ; CGRP and its receptors provide new insights into migraine pathophysiology. *Nat Rev Neurol*. 2010; 6(10):573-582
 7. Lassen LH, Haderslev PA, Jacobsen VB *et al.*; CGRP may play a causative role in migraine. *Cephalalgia* 2002; 22(1):54-61.